Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II apatinib trial in recurrent or metastatic thymic malignancies after platinum chemotherapy failure
ChiCTR-ONC-17013108Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in thymic malignancies (TET), sponsored by Zhejiang Cancer Hospital. Primary endpoint: progression-free survival. Started Oct 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
thymic malignancies (TET)
Beyond the preview
Go deeper on ChiCTR-ONC-17013108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-17013108.